Literature DB >> 22990678

Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists.

E Kirilly1, L Hunyady, G Bagdy.   

Abstract

There is strong evidence that endocannabinoids modulate signaling of serotonin and noradrenaline, which play key roles in the pathophysiology and treatment of anxiety and depression. Most pharmacological and genetic, human and rodent studies suggest that the presence of under-functioning endocannabinoid type-1 (CB(1)) receptors is associated with increased anxiety and elevated extracellular serotonin concentration. In contrast, noradrenaline is presumably implicated in the mediation of depression-type symptoms of CB(1) receptor antagonists. Evidence shows that most CB(1) receptors located on axons and terminals of GABA-ergic, serotonergic or glutamatergic neurons stimulate the activity of noradrenergic neurons. In contrast, those located on noradrenergic axons and terminals inhibit noradrenaline release efficiently. In this latter process, excitatory ionotropic or G protein-coupled receptors, such as the NMDA, alpha1 and beta1 adrenergic receptors, activate local endocannabinoid synthesis at postsynaptic sites and stimulate retrograde endocannabinoid neurotransmission acting on CB(1) receptors of noradrenergic terminals. The underlying mechanisms include calcium signal generation, which activates enzymes that increase the synthesis of both anandamide and 2-arachidonoylglycerol, while G(q/11) protein activation also increases the formation of 2-arachidonoylglycerol from diacylglycerol during the signaling process. In addition, other non-CB(1) receptor endocannabinoid targets such as CB(2), transient receptor potential vanilloid subtype, peroxisome proliferator-activated receptor-alpha and possibly GPR55 can also mediate some of the endocannabinoid effects. In conclusion, both neuronal activation and neurotransmitter release depend on the in situ synthesized endocannabinoids and thus, local endocannabinoid concentrations in different brain areas may be crucial in the net effect, namely in the regulation of neurons located postsynaptically to the noradrenergic synapse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990678     DOI: 10.1007/s00702-012-0900-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  127 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

3.  Presynaptic alpha2-adrenoceptors inhibit excitatory synaptic transmission in rat brain stem.

Authors:  M Bertolino; S Vicini; R Gillis; A Travagli
Journal:  Am J Physiol       Date:  1997-03

Review 4.  Baseline studies on transmitter substances in cerebrospinal fluid in depression.

Authors:  A Gjerris
Journal:  Acta Psychiatr Scand Suppl       Date:  1988

5.  Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function.

Authors:  Daniela Cota; Michel-Alexander Steiner; Giovanni Marsicano; Cristina Cervino; James P Herman; Yvonne Grübler; Johanna Stalla; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  Endocrinology       Date:  2006-12-28       Impact factor: 4.736

Review 6.  Affective disorders, antidepressant drugs and brain metabolism.

Authors:  A Moretti; A Gorini; R F Villa
Journal:  Mol Psychiatry       Date:  2003-09       Impact factor: 15.992

7.  Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.

Authors:  Luis M Ruilope; Jean-Pierre Després; André Scheen; Xavier Pi-Sunyer; Guiseppe Mancia; Alberto Zanchetti; Luc Van Gaal
Journal:  J Hypertens       Date:  2008-02       Impact factor: 4.844

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 9.  Pleiotropic effects of rimonabant: clinical implications.

Authors:  Jean-Pierre Després
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus.

Authors:  Leire Reguero; Nagore Puente; Izaskun Elezgarai; Juan Mendizabal-Zubiaga; Miren Josune Canduela; Ianire Buceta; Almudena Ramos; Juan Suárez; Fernando Rodríguez de Fonseca; Giovanni Marsicano; Pedro Grandes
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

View more
  12 in total

Review 1.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

Review 3.  Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder.

Authors:  Alexander Neumeister; Jordan Seidel; Benjamin J Ragen; Robert H Pietrzak
Journal:  Psychoneuroendocrinology       Date:  2014-10-22       Impact factor: 4.905

4.  Ultrastructural evidence for synaptic contacts between cortical noradrenergic afferents and endocannabinoid-synthesizing post-synaptic neurons.

Authors:  B A S Reyes; N A Heldt; K Mackie; E J Van Bockstaele
Journal:  Neuroscience       Date:  2015-07-08       Impact factor: 3.590

Review 5.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

6.  Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum.

Authors:  Ana Palomino; Francisco-Javier Pavón; Eduardo Blanco-Calvo; Antonia Serrano; Sergio Arrabal; Patricia Rivera; Francisco Alén; Antonio Vargas; Ainhoa Bilbao; Leticia Rubio; Fernando Rodríguez de Fonseca; Juan Suárez
Journal:  Front Integr Neurosci       Date:  2014-03-05

7.  24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.

Authors:  Myuri Ruthirakuhan; Nathan Herrmann; Ana C Andreazza; Nicolaas Paul L G Verhoeff; Damien Gallagher; Sandra E Black; Alex Kiss; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 8.  The endocannabinoid system in guarding against fear, anxiety and stress.

Authors:  Beat Lutz; Giovanni Marsicano; Rafael Maldonado; Cecilia J Hillard
Journal:  Nat Rev Neurosci       Date:  2015-12       Impact factor: 34.870

9.  Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation.

Authors:  Arnau Busquets-Garcia; Maria Gomis-González; Raj Kamal Srivastava; Laura Cutando; Antonio Ortega-Alvaro; Sabine Ruehle; Floortje Remmers; Laura Bindila; Luigi Bellocchio; Giovanni Marsicano; Beat Lutz; Rafael Maldonado; Andrés Ozaita
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

Review 10.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.